Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis

Abstract

Brodalumab showed an acceptable safety profile and a robust efficacy in the treatment of moderate-to-severe plaque psoriasis. However, the current evidence is insufficient to confirm maintenance of these results in the long term; therefore, larger studies with longer follow-up periods are required.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)

“…Recently, a systematic review and metaanalysis of the safety and efficacy of brodalumab for plaque psoriasis, which included in the final analysis six RCTs with more than 4000 patients, found no statistically significant differences in terms of serious adverse events or infection in the short term. Unfortunately, there was not sufficient data to confirm such a safety profile for longer exposure periods [167].…”

Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP

“…Degree of recommendation: C1. General recommendations: The efficacy and safety of secukinumab, ixekizumab and brodalumab have been demonstrated for psoriasis vulgaris, [223][224][225] psoriatic arthritis, [226][227][228] and their superior effects have been shown in several RCT over other biologics. [229][230][231][232][233][234][235] Their effects are also confirmed with Japanese populations.…”

Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors

“…Interleukin (IL)-17 is a recognised pro-inflammatory cytokine of the IL23/17 pathway, involved in the pathogenesis of several chronic inflammatory diseases (CIDs), including psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) 1 . Therefore, neutralization of IL-17, through blocking the free form (anti IL-17A drugs) or the bond to its receptor (anti IL-17R drugs), has become a molecular target for treating the aforementioned diseases [2][3][4][5][6][7] . As far as Inflammatory Bowel Diseases (IBD) are concerned, the role of IL-17 in the pathogenesis is still controversial, whereas, at the colonic mucosa level, it seems both to modulate the inflammatory response and promote wound and tissue repair [8][9][10] .…”